Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2022-06-08 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for 百奥泰生物制药股份有限公司. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The document length is 3610 characters, which is relatively short and consistent with a meeting notice. There is no indication that this is the actual meeting materials or voting results, just the notice to shareholders about the meeting and how to participate. Therefore, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings, including notices of meetings.
2022-06-08 Chinese
百奥泰 独立董事关于第二届董事会第二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding matters discussed at the second meeting of the second board of directors. It specifically addresses approval of a related-party construction contract and confirms compliance with relevant laws and regulations. The document is a formal statement of board/management opinion on governance and related-party transactions, not a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of a report publication. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management opinions.
2022-06-08 Chinese
百奥泰 独立董事关于第二届董事会第二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinions regarding matters to be discussed at the company's second board meeting of the second session. It specifically addresses the approval of a related-party construction contract and related transactions. The content focuses on governance and board-level decisions rather than financial results, audit opinions, or shareholder voting outcomes. There is no indication of financial data, earnings, or regulatory filings. The document is related to board/management information, specifically the independent directors' opinions on board meeting matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and does not represent a full report or announcement of a report publication, so it is not RPA or RNS.
2022-06-08 Chinese
百奥泰 关于完成法定代表人变更并换领营业执照的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's legal representative and the completion of related business license registration. It includes details about the new legal representative, company registration information, and references a previous announcement about board election. There is no financial data, no report or presentation content, and it is not a regulatory certification or voting result. The document is about management information, specifically a change in the company's board chairman and legal representative. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is a direct announcement, not a report publication or regulatory filing.
2022-06-08 Chinese
百奥泰 关于召开2021年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2021 annual performance explanation meeting (业绩说明会) by 百奥泰生物制药股份有限公司. It mentions that the 2021 annual report has already been disclosed on April 29, 2022, and this document is inviting investors to participate in an online meeting to discuss the 2021 results. The document does not contain any financial data or detailed report content itself, but rather provides logistical information about the meeting, how to participate, and contact details. The document length is short (1446 characters), and it is clearly an announcement of a meeting related to the annual report, not the report itself. Therefore, it fits the category of Investor Presentation (IP) or possibly AGM Information (AGM-R). However, since it is specifically about an annual performance explanation meeting (业绩说明会), which is typically an investor presentation focused on financial results and company strategy, the best fit is Investor Presentation (IP).
2022-05-31 Chinese
百奥泰 2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2021 Annual General Meeting (AGM) of 百奥泰生物制药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, board reports, financial statements, profit distribution, remuneration plans, appointment of auditors, credit facilities, and election of board members and supervisors. The document also confirms the legality and validity of the meeting and voting process, witnessed by lawyers. This type of document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the full annual report itself, nor a proxy statement or management report. The length and detail confirm it is not a brief announcement or a simple notice but a full voting results announcement.
2022-05-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.